Osaic Holdings’s Gyre Therapeutics GYRE Stock Holding History

Osaic Holdings’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$265	Hold	38	–	–	﹤0.01%	7523
2025 Q4	$268	Hold	38	–	–	﹤0.01%	7539
2025 Q3	$283	Hold	38	–	–	﹤0.01%	7647
2025 Q2	$279	Buy	38 +27	+245%	+$236	﹤0.01%	7459
2025 Q1	$85	Sell	11 -30	-73%	-$329	﹤0.01%	7249
2024 Q4	$496	Sell	41 -400	-91%	-$5.12K	﹤0.01%	7023
2024 Q3	$5.53K	Sell	441 -200	-31%	-$2.58K	﹤0.01%	6150
2024 Q2	$7.65K	Buy	641 +627	+4,479%	+$8.6K	﹤0.01%	5947
2024 Q1	$245	Hold	14	–	–	﹤0.01%	6942
2023 Q4	$360	Sell	14 -12	-46%	-$170	﹤0.01%	6940
2023 Q3	$188	Buy	26 +12	+86%	+$80	﹤0.01%	7160
2023 Q2	$76	Hold	14	–	–	﹤0.01%	7307
2023 Q1	$45	Sell	14 -15	-52%	-$57	﹤0.01%	7383
2022 Q4	$113	Buy	+29	New	+$118	﹤0.01%	7116

Other funds holding GYRE

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Osaic Holdings's GYRE Position: Q1 2026 in Review

Osaic Holdings held its Gyre Therapeutics (GYRE) position steady in Q1 2026 at 38 shares worth $265. The position accounts for ﹤0.01% of the portfolio, ranked #7523.

Osaic Holdings first reported a position in GYRE in Q4 2022 and has held it in 14 quarters since. The position peaked at $7.65K in Q2 2024. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.

Osaic Holdings held 38 shares of Gyre Therapeutics worth $265 as of Q1 2026.
Osaic Holdings left its Gyre Therapeutics share count unchanged in Q1 2026.
Gyre Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q1 2026, its #7523 holding.
Osaic Holdings first reported a position in Gyre Therapeutics in Q4 2022 and has held it in 14 quarters since.
Osaic Holdings's Gyre Therapeutics position peaked at $7.65K in Q2 2024.
56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.

Based on Osaic Holdings's 13F filing for Q1 2026, filed 15 May 2026.